Bradmer Pharmaceuticals Inc. (TSE:GLX – Get Free Report) has been given an average rating of “Buy” by the eight brokerages that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and five have given a strong buy recommendation to the company.
GLX has been the subject of a number of research reports. Citizens Jmp upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, December 9th. ATB Cormark Capital Markets lowered Bradmer Pharmaceuticals from a “strong-buy” rating to a “moderate buy” rating in a research note on Thursday, February 5th. Finally, Citigroup raised shares of Bradmer Pharmaceuticals to a “hold” rating in a research note on Tuesday.
Get Our Latest Stock Report on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Stock Performance
Featured Articles
- Five stocks we like better than Bradmer Pharmaceuticals
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- The Biggest IPO Ever… Open to Everyday Folks
- Silver records prices are great. Monthly income is better
- Read this or regret it forever
- Sell this, buy that
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
